SRINI PHARMACEUTICALS
SRINI PHARMACEUTICALS, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of high-quality generic and specialty medicines. Founded in 1990, the company has established a strong presence in various operational regions, including Asia, Europe, and North America. With a commitment to innovation, SRINI PHARMACEUTICALS offers a diverse portfolio of products, including formulations for chronic and acute conditions, which are distinguished by their efficacy and affordability. The company has achieved significant milestones, including regulatory approvals from major health authorities, solidifying its market position as a trusted provider of pharmaceutical solutions. SRINI PHARMACEUTICALS continues to focus on research and development, ensuring it meets the evolving needs of healthcare professionals and patients worldwide.
DitchCarbon Score
How does SRINI PHARMACEUTICALS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SRINI PHARMACEUTICALS's score of 4 is lower than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SRINI PHARMACEUTICALS's reported carbon emissions
SRINI PHARMACEUTICALS, headquartered in India, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that SRINI PHARMACEUTICALS may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). As the pharmaceutical industry increasingly prioritises sustainability, SRINI PHARMACEUTICALS may need to consider developing and communicating its climate commitments to align with global efforts in reducing greenhouse gas emissions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SRINI PHARMACEUTICALS is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
